Anton Giorgio Failla

Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC.

MicroPort CRM SRL engages in the production and distribution of medical devices. It specializes in the development of medical technologies for the treatment of cardiovascular diseases. The company is headquartered in Saluggia, Italy.

Novartis Consumer Health engages in the provision of healthcare services. The company is headquartered in Swaziland.

Bellco SRL provides therapies and systems for the treatment of renal failure, multiple organ failure, sepsis and congestive heart failure. It offers haemodiafiltration therapies, dialysis machines equipment, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges; pathologies for acute patients; and altered haemodynamics, renal hypoperfusion, and low cardiac output therapeutic system for neonatal patients. The company was founded in 1972 and is headquartered in Mirandola, Italy.^

Sorin Biomedica SRL manufactures medical electro medical systems and equipment. The company is headquartered in Saluggia, Italy.

Part of LivaNova Plc, Biofin Holding International NV is an Italian company that distributes medical devices. The company is based in Milan, Italy.

Sorin CRM SAS designs and manufactures implantable pacemakers and defibrillators. It offers ICDs, leads, holter equipment, and electrophysiology catheters. The company was founded on July 25, 1977 and is headquartered in Clamart, France.

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.